The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
dc.contributor.author | Turk, Can | |
dc.contributor.author | Okay, Mufide | |
dc.contributor.author | Turk, Seyhan | |
dc.contributor.author | Temirci, Elif Sena | |
dc.contributor.author | Javad, Osama | |
dc.contributor.author | Aksu, Sal | |
dc.contributor.author | Sayinalp, Nilgun | |
dc.contributor.author | Haznedaroglu, Ibrahim Celalettin | |
dc.date.accessioned | 2020-10-26T12:24:22Z | |
dc.date.available | 2020-10-26T12:24:22Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.3906/sag-1807-152 | |
dc.identifier.issn | 1300-0144 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12591/309 | |
dc.source | Turkish Journal of Medical Sciences | |
dc.title | The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases |